These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29019267)

  • 1. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways.
    Pi J; Jiang J; Cai H; Yang F; Jin H; Yang P; Cai J; Chen ZW
    Drug Deliv; 2017 Nov; 24(1):1549-1564. PubMed ID: 29019267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional graphene oxide as cancer-targeted drug delivery system to selectively induce oesophageal cancer cell apoptosis.
    Jiang JH; Pi J; Jin H; Cai JY
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S297-S307. PubMed ID: 30183382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
    Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
    Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin.
    Xu J; Zhao JH; Liu Y; Feng NP; Zhang YT
    Int J Nanomedicine; 2012; 7():211-9. PubMed ID: 22275836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bee venom-loaded EGFR-targeting peptide-coupled chitosan nanoparticles for effective therapy of hepatocellular carcinoma by inhibiting EGFR-mediated MEK/ERK pathway.
    Abdulmalek S; Mostafa N; Gomaa M; El-Kersh M; Elkady AI; Balbaa M
    PLoS One; 2022; 17(8):e0272776. PubMed ID: 35947632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oridonin-induced mitochondria-dependent apoptosis in esophageal cancer cells by inhibiting PI3K/AKT/mTOR and Ras/Raf pathways.
    Jiang JH; Pi J; Jin H; Cai JY
    J Cell Biochem; 2019 Mar; 120(3):3736-3746. PubMed ID: 30229997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single molecule force spectroscopy for in-situ probing oridonin inhibited ROS-mediated EGF-EGFR interactions in living KYSE-150 cells.
    Pi J; Jin H; Jiang J; Yang F; Cai H; Yang P; Cai J; Chen ZW
    Pharmacol Res; 2017 May; 119():479-489. PubMed ID: 28411855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression.
    Go G; Park HJ; Lee JH; Yun CW; Lee SH
    Anticancer Res; 2022 Feb; 42(2):857-866. PubMed ID: 35093883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers.
    Xu WW; Liu DY; Cao YC; Wang XY
    Int J Nanomedicine; 2017; 12():6461-6470. PubMed ID: 28919747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.
    Xiao X; He Z; Cao W; Cai F; Zhang L; Huang Q; Fan C; Duan C; Wang X; Wang J; Liu Y
    Int J Oncol; 2016 Jun; 48(6):2608-18. PubMed ID: 27082429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy.
    Xia Y; Xiao M; Zhao M; Xu T; Guo M; Wang C; Li Y; Zhu B; Liu H
    Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110100. PubMed ID: 31753388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma.
    Xu ZZ; Fu WB; Jin Z; Guo P; Wang WF; Li JM
    Leuk Lymphoma; 2016; 57(4):888-98. PubMed ID: 26415087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angelica Sinensis Polysaccharide-Based Nanoparticles for Liver-Targeted Delivery of Oridonin.
    Sun H; Nai J; Deng B; Zheng Z; Chen X; Zhang C; Sheng H; Zhu L
    Molecules; 2024 Feb; 29(3):. PubMed ID: 38338476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.
    Zheng D; Duan C; Zhang D; Jia L; Liu G; Liu Y; Wang F; Li C; Guo H; Zhang Q
    Int J Pharm; 2012 Oct; 436(1-2):379-86. PubMed ID: 22732673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
    Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
    Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR-targeting peptide conjugated polymer-lipid hybrid nanoparticles for delivery of salinomycin to osteosarcoma.
    Du L; Xu Y; Han B; Wang Y; Zeng Q; Shao M; Yu Z
    J Cancer Res Ther; 2023 Dec; 19(6):1544-1551. PubMed ID: 38156920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel galactosylated biodegradable nanoparticles for hepatocyte-delivery of oridonin.
    Wang Y; Liu X; Liu G; Guo H; Li C; Zhang Y; Zhang F; Zhao Z; Cheng H
    Int J Pharm; 2016 Apr; 502(1-2):47-60. PubMed ID: 26911417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation.
    Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW
    Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway.
    Cao S; Xia M; Mao Y; Zhang Q; Donkor PO; Qiu F; Kang N
    Int J Oncol; 2016 Nov; 49(5):2075-2087. PubMed ID: 27667173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.